MovDisordV3, Main, Curation, bibRecord, 003850

Methadone for refractory restless legs syndrome

Identifieur interne : 003850 ( Main/Curation ); précédent : 003849; suivant : 003851

Methadone for refractory restless legs syndrome

Auteurs : William G. Ondo [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2005-03.

RBID : ISTEX:4D639917C3D66D247999F7C3E6F89969F9E02985

English descriptors

KwdEn :
- Adult, Aged, Aged, 80 and over, Analgesics, Opioid (administration & dosage), Analgesics, Opioid (therapeutic use), Drug Administration Schedule, Female, Humans, Male, Methadone (administration & dosage), Methadone (therapeutic use), Middle Aged, Restless Legs Syndrome (drug therapy), augmentation, dopaminergics, methadone, restless legs syndrome.
MESH :
- chemical , administration & dosage : Analgesics, Opioid, Methadone.
- chemical , therapeutic use : Analgesics, Opioid, Methadone.
- drug therapy : Restless Legs Syndrome.
- Adult, Aged, Aged, 80 and over, Drug Administration Schedule, Female, Humans, Male, Middle Aged.

Abstract

Most cases of restless legs syndrome (RLS) initially respond well to dopaminergic agonists. However, an unknown percentage of patients is intolerant of dopaminergic adverse events, initially or subsequently refractory, or develops limiting augmentation. We administered methadone 5 to 40 mg/day (final dose, 15.6 ± 7.7) to 29 RLS patients who failed dopaminergics. They were currently taking or had previously tried 5.9 ± 1.7 (range, 3–9) different medications for RLS and 2.9 ± 0.8 (range, 2–4) different dopaminergics. Of the 27 patients who met inclusion criteria, 17 have remained on methadone for 23 ± 12 months (range, 4–44 months) at a dose of 15.5 ± 7.7 mg/day; 2 dialysis RLS patients died while on methadone, and 8 stopped the treatment (5 for adverse events, 2 for lack of efficacy, and 1 for logistical reasons). All patients who remain on methadone report at least a 75% reduction in symptoms, and none have developed augmentation. Methadone should be considered in RLS patients with an unsatisfactory dopaminergic response. © 2004 Movement Disorder Society

Url:

https://api.istex.fr/document/4D639917C3D66D247999F7C3E6F89969F9E02985/fulltext/pdf

DOI: 10.1002/mds.20359

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002C55
to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :002C55
to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002258
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003194
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003194
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003063
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001107
to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001107
to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001107
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :004F35

Links to Exploration step

ISTEX:4D639917C3D66D247999F7C3E6F89969F9E02985

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Methadone for refractory restless legs syndrome</title>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4D639917C3D66D247999F7C3E6F89969F9E02985</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20359</idno>
<idno type="url">https://api.istex.fr/document/4D639917C3D66D247999F7C3E6F89969F9E02985/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002C55</idno>
<idno type="wicri:Area/Istex/Curation">002C55</idno>
<idno type="wicri:Area/Istex/Checkpoint">002258</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Ondo W:methadone:for:refractory</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15580610</idno>
<idno type="wicri:Area/PubMed/Corpus">003194</idno>
<idno type="wicri:Area/PubMed/Curation">003194</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003063</idno>
<idno type="wicri:Area/Ncbi/Merge">001107</idno>
<idno type="wicri:Area/Ncbi/Curation">001107</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001107</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Ondo W:methadone:for:refractory</idno>
<idno type="wicri:Area/Main/Merge">004F35</idno>
<idno type="wicri:Area/Main/Curation">003850</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Methadone for refractory restless legs syndrome</title>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baylor College of Medicine, Houston Texas</wicri:regionArea>
<wicri:noRegion>Houston Texas</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-03">2005-03</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="345">345</biblScope>
<biblScope unit="page" to="348">348</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">4D639917C3D66D247999F7C3E6F89969F9E02985</idno>
<idno type="DOI">10.1002/mds.20359</idno>
<idno type="ArticleID">MDS20359</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Analgesics, Opioid (administration & dosage)</term>
<term>Analgesics, Opioid (therapeutic use)</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Methadone (administration & dosage)</term>
<term>Methadone (therapeutic use)</term>
<term>Middle Aged</term>
<term>Restless Legs Syndrome (drug therapy)</term>
<term>augmentation</term>
<term>dopaminergics</term>
<term>methadone</term>
<term>restless legs syndrome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Analgesics, Opioid</term>
<term>Methadone</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Analgesics, Opioid</term>
<term>Methadone</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Restless Legs Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Most cases of restless legs syndrome (RLS) initially respond well to dopaminergic agonists. However, an unknown percentage of patients is intolerant of dopaminergic adverse events, initially or subsequently refractory, or develops limiting augmentation. We administered methadone 5 to 40 mg/day (final dose, 15.6 ± 7.7) to 29 RLS patients who failed dopaminergics. They were currently taking or had previously tried 5.9 ± 1.7 (range, 3–9) different medications for RLS and 2.9 ± 0.8 (range, 2–4) different dopaminergics. Of the 27 patients who met inclusion criteria, 17 have remained on methadone for 23 ± 12 months (range, 4–44 months) at a dose of 15.5 ± 7.7 mg/day; 2 dialysis RLS patients died while on methadone, and 8 stopped the treatment (5 for adverse events, 2 for lack of efficacy, and 1 for logistical reasons). All patients who remain on methadone report at least a 75% reduction in symptoms, and none have developed augmentation. Methadone should be considered in RLS patients with an unsatisfactory dopaminergic response. © 2004 Movement Disorder Society</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003850 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003850 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     ISTEX:4D639917C3D66D247999F7C3E6F89969F9E02985
   |texte=   Methadone for refractory restless legs syndrome
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Methadone for refractory restless legs syndrome

Methadone for refractory restless legs syndrome

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri